Patient monitoring and decision-making in CIDP
How should patients with CIDP be monitored over time, and when should treatment strategies be adjusted? In this interview, Lars Kjøbsted Markvardsen, Specialist in Neurology, Aarhus University Hospital, Denmark, discusses treatment pathways in CIDP, including the shift from hospital-based to home-based immunoglobulin therapy, and the importance of ongoing patient monitoring and dose reassessment to ensure optimal long-term outcomes.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
